<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941626</url>
  </required_header>
  <id_info>
    <org_study_id>2019BDB016</org_study_id>
    <nct_id>NCT03941626</nct_id>
  </id_info>
  <brief_title>Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies</brief_title>
  <official_title>EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen BinDeBio Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen BinDeBio Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and&#xD;
      effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-target gene-modified immunotherapy. CAR-T/TCR-T cells include four&#xD;
      different tumor-specific antibody.They are as following:anti-NY-ESO-1 antibody foresophagus&#xD;
      cancer;anti-DR5 antibody for hepatoma;;anti-EGFR vIII antibody for hepatoma and&#xD;
      glioma;anti-Mesothelin antibody for gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0</measure>
    <time_frame>48 months</time_frame>
    <description>Safety evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>48 months</time_frame>
    <description>Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, magnetic resonance imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophagus Cancer</condition>
  <condition>Hepatoma</condition>
  <condition>Glioma</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>CAR-T/TCR-T cells immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T/TCR-T cells immunotherapy</intervention_name>
    <description>According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.</description>
    <arm_group_label>CAR-T/TCR-T cells immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be willing to sign an informed consent.&#xD;
&#xD;
          2. Male or female patients aged 18 to 70 years .&#xD;
&#xD;
          3. Estimated survival of ≥ 12 weeks.&#xD;
&#xD;
          4. Pathological sections with positive expression of NY-ESO-1, Mesothelin, EGFRvIII and&#xD;
             DR5 was confirmed by biopsy IHC test within 12 months.If NY-ESO-1 is positive&#xD;
             expression ,positive HLAA*0201 is required at the same time.&#xD;
&#xD;
          5. Solid tumor must have at least one measureable disease according to RECIST 1.1.&#xD;
&#xD;
          6. Routine blood test#hemoglobin&gt;=90 g/L; platelet&gt;=50×10^9/L.&#xD;
&#xD;
          7. Liver function:ALT and AST≤2.5 times upper limits of normal (If the tumor infiltration&#xD;
             is the main cause of abnormal liver function ,ALT and AST≤5 times upper limits of&#xD;
             normal); bilirubin&lt;2.0 mg/dL.&#xD;
&#xD;
          8. Renal function:BUN: 9-20mg / dl; serum creatinine≤ 1.5 times upper limits of normal;&#xD;
             endogenous creatinine clearance rate≥50 ml/min .&#xD;
&#xD;
          9. Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV.&#xD;
&#xD;
         10. Cardiac function: stable hemodynamic and left ventricular ejection fraction&#xD;
             (LVEF)&gt;=55%.&#xD;
&#xD;
         11. ECOG score:0-1.&#xD;
&#xD;
         12. Adequate venous access for apheresis, and no other contraindications for leukapheresis&#xD;
             .&#xD;
&#xD;
         13. Women of child-bearing age must have evidence of negative pregnancy test. Subjects of&#xD;
             reproductive potential must agree to use acceptable birth control methods within 1&#xD;
             year after treatment, as described in protocol.&#xD;
&#xD;
         14. Subjects with hypertension/diabetes must be stable blood pressure/blood glucose or&#xD;
             ≤CTCAE 1 level 2 weeks before the screening.&#xD;
&#xD;
        In addition to the above criteria for inclusion, the following criteria shall be met&#xD;
        according to the indications:&#xD;
&#xD;
        Patients with glioblastoma：&#xD;
&#xD;
          1. First disease progression or disease recurrence (≥ 1 cm and ≤ 5 cm) of a&#xD;
             supratentorial WHO grade IV malignant glioma (GBM or gliosarcoma) based on imaging&#xD;
             studies with measurable disease.&#xD;
&#xD;
          2. EGFRvIII, the target antigen, must be identified on tumor tissue by IHC or PCR, i.e.&#xD;
             EGFRvIII positive via pathology report.&#xD;
&#xD;
          3. Insensitivity to chemoradiotherapy or chemoradiotherapy failure after operation&#xD;
             molecular pathology.&#xD;
&#xD;
          4. Refused to receive radiotherapy or chemotherapy treatment.&#xD;
&#xD;
        Patients with liver cancer&#xD;
&#xD;
          1. DR5 or EGFRvIII positive via pathology report.&#xD;
&#xD;
          2. Untreatable by surgery ; Or postoperative recurrence ;Or no effective treatment.&#xD;
&#xD;
          3. Liver function：child-pugh A grade or child-pugh B grade.&#xD;
&#xD;
        Patients with gastric cancer&#xD;
&#xD;
          1. Mesothelin positive via pathology report.&#xD;
&#xD;
          2. The pathological stage：IIIA～IV.&#xD;
&#xD;
          3. chemoradiotherapy failure&#xD;
&#xD;
          4. Refused or unable to get surgery.&#xD;
&#xD;
        Patients with esophageal cancer&#xD;
&#xD;
          1. NY-ESO-1 positive via pathology report and HLA-A*0201 positive in blood.&#xD;
&#xD;
          2. Refuse or unable to get surgery.&#xD;
&#xD;
          3. Postoperative recurrence or chemoradiotherapy failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ECOG≥2.&#xD;
&#xD;
          2. malignant tumor cells with T cell origin via pathology test.&#xD;
&#xD;
          3. Organ failure: stage III or IV congestive heart failure; Renal failure and uremia;&#xD;
             respiratory failure; disturbance of consciousness.&#xD;
&#xD;
          4. Acute or chronic GVHD after allogeneic hematopoiesis; Or being treated for GVHD; Or&#xD;
             hormone or immunosuppressant used within 30 days&#xD;
&#xD;
          5. steroid hormoneswere used before and after blood collection and infusion&#xD;
&#xD;
          6. Patients with HIV infection or active hepatitis&#xD;
&#xD;
          7. Uncontrolled active infection.&#xD;
&#xD;
          8. Enrolled to other clinical study in the last 4 weeks.&#xD;
&#xD;
          9. Patients with systemic auto-immune disease or immunodeficiency.&#xD;
&#xD;
         10. Patients with neuropathy or psychosis, including dementia or epilepsy, or history of&#xD;
             psychotropic substance abuse, or other substantial lesions that may increase central&#xD;
             neurotoxicity.&#xD;
&#xD;
         11. Concomitant with the second tumor or other malignant tumors.&#xD;
&#xD;
         12. Patients with bone metastases are at risk of a pathological fracture resulting in&#xD;
             paraplegia or life threatening.&#xD;
&#xD;
         13. Live attenuated vaccine was administered within 4 weeks prior to blood collection.&#xD;
&#xD;
         14. Blood oxygen saturation is maintained by oxygen inhalation.&#xD;
&#xD;
         15. Received major surgery within 2 weeks prior to screening ;Or Plan to receive surgery&#xD;
             during study or within 2 weeks after injection.&#xD;
&#xD;
         16. Other patients that researchers considered unsuitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ZHONG HUA YANG</last_name>
    <phone>+8618938688105</phone>
    <phone_ext>+8618938688105</phone_ext>
    <email>zh.yang@bindebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangyin Han</last_name>
      <phone>+8613203710057</phone>
      <email>hansyzzu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Chun-Xiao Ma</last_name>
      <phone>+8615038287266</phone>
      <email>chxma@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shuangyin Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Xiao Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

